INY-05-040

INY-05-040 is an AKT degrader that can selectively and quickly degrade all three AKT isoforms. INY-05-040 exhibits anti-cancer activity. INY-05-040 can inhibit downstream signaling and cell proliferation in 288 cancer cell lines. INY-05-040 can suppress AKT signaling and induces the stress mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK) . INY-05-040 is effective for breast cancer lines with a low-baseline activation of stress MAPK pathway. INY-05-040 can be studied for anti-cancer research[1][2][3].

Product Specifications

CAS Number

[2503018-29-7]

UNSPSC

12352005

Target

Akt; PROTACs

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; PROTAC

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iny-05-040.html

Purity

98.67

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@H]1C2=C(N3CCN(CC3)C([C@@H](C4=CC=C(C=C4)Cl)CNCCCCCCCCCCC(N[C@@H](C(C)(C)C)C(N5[C@@H](C[C@H](C5)O)C(N[C@H](C6=CC=C(C7=C(C)N=CS7)C=C6)C)=O)=O)=O)=O)N=CN=C2[C@@H](C1)O

Molecular Formula

C55H76ClN9O6S

Molecular Weight

1026.77

References & Citations

[1]Erickson E C, et al. Multi-omic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation[J]. bioRxiv, 2022: 2022.10. 11.511726.|[2]Chen, C., et al., (2024) . Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors. Cells, 13 (12), 1061.|[3]Wu, Y., et al., (2025) . Pharmacodynamics of Akt drugs revealed by a kinase-modulated bioluminescent indicator. Nature chemical biology, 21 (8), 1194–1204.